RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.
2 Sep, 2021 | 10:17h | UTCCommentaries:
Commentaries on Twitter
NEW—Baricitinib did not improve the composite primary endpoint of progression to NIV,
high-flow O2, IMV, or death; however, it did reduce 28-day all-cause mortality by 38·2% vs placebo (HR 0·57 [95% CI 0·41–0·78])Read the COV-BARRIER study: https://t.co/QrU6GW0XcQ#ISICEM2021
— The Lancet Respiratory Medicine (@LancetRespirMed) September 1, 2021
(thread – click for more)
1/?? NEW COVID THERAPY SAVES LIVES
Adding baricitinib to steroids will save 1,000s of hospitalized #COVID pts. Our @LancetRespirMed COV-Barrier study is FREE.
I explain?why it’s such a great #Pandemic discovery story: a new way to ⬇️ COVID19 deaths.https://t.co/8I5BlwyT2R pic.twitter.com/6KcfQrljqC
— WesElyMD (@WesElyMD) September 1, 2021